Biomarker News and Research

RSS

A biomarker is a biological molecule found in blood, other body fluids, or tissues that is a sign of a normal or abnormal process, or of a condition or disease. A biomarker may be used to see how well the body responds to a treatment for a disease or condition. Also called molecular marker and signature molecule.

Researchers discover biomarker for allergy can originate from mother

Allergies occur when the defence mechanisms of the immune system malfunction and misread normal substances entering the body as invading pathogens. Antibodies are part of our biochemical arsenal for combating viruses, bacteria, parasites and other alien substances, but during an allergic reaction the antibody, known as IgE, is directed against usually harmless substances such as grass pollen, nuts, pets or eggs. However, researchers from COPSAC (Copenhagen Studies on Asthma in Childhood) at the Faculty of Health Sciences, University of Copenhagen recently discovered indications that IgE in the blood of the umbilical cord could originate from the mother, and decided to conduct a focused study on this.

6 Oct 2010

Cancer cells utilize energy-rich intermediates of sugar metabolism: Research

Cancer research is facing a radical change of direction. Cancer cells do not obtain their energy from the breakdown of sugar to carbon dioxide and water, but from energy-rich intermediates of sugar metabolism instead.

6 Oct 2010

Lixte, NCI collaborate for clinical evaluation of LB-100 compound

Lixte Biotechnology Holdings announced today that the National Cancer Institute Experimental Therapeutics (NExT) Program Senior Advisory Committee (SAC), Division of Cancer Treatment and Diagnosis (DCTD), National Cancer Institute (NCI), National Institutes of Health (NIH), signed a NExT Material Transfer Agreement formalizing a collaboration with Lixte Biotechnology Holdings, Inc. for clinical evaluation of LB-100, one of Lixte's lead anti-cancer compounds.

6 Oct 2010

MRI technique may help predict decline in individuals with mild cognitive impairment

Using advanced MRI and an artificial intelligence technique, researchers in Geneva, Switzerland, have identified a method that may help identify which individuals with mild cognitive impairment (MCI) will continue to decline, according to a study published online and in the December issue of Radiology.

5 Oct 2010

Merck Serono to present Erbitux data at ESMO Congress

Merck Serono, a division of Merck KGaA, Darmstadt, Germany announces today that it will be presenting new data from several studies of Erbitux (cetuximab) in a range of solid tumor types including the first Phase II data in breast and prostate cancers. These data will be presented at the forthcoming 35th European Society for Medical Oncology Congress (ESMO) in Milan, October 8-12, 2010.

5 Oct 2010

mtDNA deletion: New biomarker for identifying malignant prostate cancer

Mitomics, world leader in the research and development of mitochondrial genome-based products to improve clinical insight and therapeutic decisions, today announced the publication of new research in the Canadian Urological Association Journal (CUAJ) showing that large-scale deletions in mitochondrial DNA (mtDNA) can indicate cellular changes that are associated with the development of cancer.

5 Oct 2010

Amgen announces PRIME '203' and '181' Phase 3 trial results

Amgen today announced that results from the PRIME '203' and '181' pivotal Phase 3 trials evaluating Vectibix (panitumumab) in combination with chemotherapy (FOLFOX or FOLFIRI) as a first and second-line treatment for metastatic colorectal cancer (mCRC), respectively, were published online in the Journal of Clinical Oncology.

5 Oct 2010

Gentel Biosciences, RayBiotech to develop antibody array products with APiX chromogenic detection platform

Gentel Biosciences, a leader in proteomics profiling tools and RayBiotech, Inc., a pioneer and leader in protein and antibody array technologies, jointly announce today their partnership to develop and market RayBiotech's vast collection of antibody array products covering a wide variety of cytokines and other proteins for use with Gentel's APiX chromogenic detection platform.

5 Oct 2010

Neuro-Biotech introduces biomarker for progressive clinical investigation on Alzheimer's Disease

Neuro-Biotech Corporation introduces a Neuro-biomarker which is linked to a series of Neuro-Bio tests. This will permit to understand the science behind them and how they each will contribute to a progressive clinical investigation involving the input and output of the brain.

5 Oct 2010

Reduced levels of brain-derived neurotrophic factor are a trait marker for psychogenic non-epileptic seizures

New research from Rhode Island Hospital found that reduced levels of brain-derived neurotrophic factor (BDNF), a protein in the brain that encourages growth of neurons, may be a trait marker for individuals with psychogenic non-epileptic seizures (PNES) (seizures that are psychological in origin). The findings are published in the October 4, 2010, issue of Neurology, the medical journal of the American Academy of Neurology.

5 Oct 2010

Aeras Global receives FDA grant to develop biomarkers for TB vaccine

The Aeras Global TB Vaccine Foundation is pleased to announce receipt of a grant from the United States Food and Drug Administration (FDA) to develop new biological and immunological biomarkers for TB vaccine development. The FDA grant, which supports the coordination of a multi-investigator project with researchers from the United States, the United Kingdom and South Africa, will provide $362,102 in the first year of funding.

5 Oct 2010

NIH awards contract to develop nanotechnology tools for atherosclerosis treatment

Georgia Tech and Emory University have received a five-year $14.6 million contract from the National Institutes of Health (NIH) to continue the development of nanotechnology and biomolecular engineering tools and methodologies for detecting and treating atherosclerosis.

5 Oct 2010

New SymPath kit measures DBH activity of Sympathetic Nervous System

Biotech Corporation in acquiring licenses to commercialize 12 Neuro-biomarkers has first focused on SymPath(R) and is now ready to give you the opportunity to shed some light about this Neuro-biomarker of the Sympathetic Nervous System (SNS). Here is a peak into the research behind the Neuro-blood testing that will be available to all patients through their health system.

4 Oct 2010

AVEO Pharmaceuticals to present tivozanib Phase 2 study results at IKCS Symposium

AVEO Pharmaceuticals, Inc., a biopharmaceutical company focused on discovering, developing and commercializing cancer therapeutics, today announced that previously reported results from its Phase 2 study evaluating tivozanib for the treatment of advanced renal cell carcinoma (RCC) will be presented at the Ninth International Kidney Cancer Symposium (IKCS) in Chicago, Illinois, October 1-2, 2010.

4 Oct 2010

VirtualScopics third-quarter revenues increase 25% to $3.5 million

VirtualScopics, Inc., a provider of quantitative imaging for clinical trials, today announced revenues for the third quarter ended September 30, 2010 exceeded $3.5 million, representing a greater than 25% increase over the comparable period in 2009 and a greater than 9% growth over the preceding quarter ended June 30, 2010. Year-to-date revenues increased over 30% for the period ended September 30, 2010 compared to the same period in 2009.

1 Oct 2010

Aethlon Medical engages Fabiani & Company to assist in establishment of federal partnerships

Aethlon Medical, Inc., the pioneer in developing therapeutic filtration devices to address infectious disease and cancer, announced today that it has engaged Fabiani & Company to assist in the establishment of federal partnerships that advance biodefense, cancer, and chronic infectious disease applications of the Aethlon Hemopurifier®.

30 Sep 2010

Agilent introduces SureSelect Kinome Target Enrichment Kit to focus next-generation sequencing studies

Agilent Technologies Inc. today introduced the SureSelect Kinome Target Enrichment Kit, enabling researchers to focus next generation sequencing studies on expressed kinases (the kinome). Researchers increasingly are looking at human kinases as a rich, proven source of biomarkers as well as potential drug targets for cancers and other diseases.

30 Sep 2010

Penn Medicine selected as study site for PPMI

The Penn Medicine Parkinson's Disease and Movement Disorders Center announced that it is one of 18 official study sites for the Parkinson's Progression Markers Initiative (PPMI), a landmark observational clinical study sponsored by The Michael J. Fox Foundation, which will use a combination of advanced imaging, biologics sampling and behavioral assessments to identify biomarkers of Parkinson's disease progression.

30 Sep 2010

AccuPSA test for detecting prostate cancer recurrence

A new test could reliably detect early increases in prostate specific antigen (PSA) levels a biomarker commonly used to measure the recurrence of prostate cancer in men who have undergone prostate cancer treating surgery. Earlier detection of these rising levels would allow men with cancer recurrence to undergo earlier, more effective treatment for potentially better outcomes.

30 Sep 2010

Unique genetic markers point to patient response to SCV-07 treatment

SciClone Pharmaceuticals, Inc. (NASDAQ: SCLN) today announced that researchers have identified two unique gene clusters that differentiated subjects who responded to treatment in the Company’s phase 2a proof of concept study of SCV-07 for the prevention of severe oral mucositis (OM; WHO grades 3-4) in patients with advanced head and neck cancer.

29 Sep 2010

Biomarker News and Research

Further Reading

Researchers discover biomarker for allergy can originate from mother

Cancer cells utilize energy-rich intermediates of sugar metabolism: Research

Lixte, NCI collaborate for clinical evaluation of LB-100 compound

MRI technique may help predict decline in individuals with mild cognitive impairment

Merck Serono to present Erbitux data at ESMO Congress

mtDNA deletion: New biomarker for identifying malignant prostate cancer

Amgen announces PRIME '203' and '181' Phase 3 trial results

Gentel Biosciences, RayBiotech to develop antibody array products with APiX chromogenic detection platform

Neuro-Biotech introduces biomarker for progressive clinical investigation on Alzheimer's Disease

Reduced levels of brain-derived neurotrophic factor are a trait marker for psychogenic non-epileptic seizures

Aeras Global receives FDA grant to develop biomarkers for TB vaccine

NIH awards contract to develop nanotechnology tools for atherosclerosis treatment

New SymPath kit measures DBH activity of Sympathetic Nervous System

AVEO Pharmaceuticals to present tivozanib Phase 2 study results at IKCS Symposium

VirtualScopics third-quarter revenues increase 25% to $3.5 million

Aethlon Medical engages Fabiani & Company to assist in establishment of federal partnerships

Agilent introduces SureSelect Kinome Target Enrichment Kit to focus next-generation sequencing studies

Penn Medicine selected as study site for PPMI

AccuPSA test for detecting prostate cancer recurrence

Unique genetic markers point to patient response to SCV-07 treatment

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

From Puberty to Menopause: Clue’s CEO, Audrey Tsang on the Power of Femtech

Latest Life Science News